• NEWS
    • Cover Features
    • Latest News
    • Job Movements
    • Startup Marvels
    • Good Deeds – CSR
    • Workplace Cultures
  • BRANDS
    • Campaigns
    • Spotlight
  • LEADERSHIP
    • Global Leaders
    • Incredible Journeys
    • The Founder
    • PRO Speak
  • INDUSTRY
    • Education
    • Modern Healthcare
    • Travel & Tourism
  • FEATURES
    • Life
    • B&L Dialogue
    • Videos Series
  • About Us
    • Brands and Leaders INDIA
    • Advertise with us
    • Privacy Policy
    • Contact Us
  • NEWS
    • Cover Features
    • Latest News
    • Job Movements
    • Startup Marvels
    • Good Deeds – CSR
    • Workplace Cultures
  • BRANDS
    • Campaigns
    • Spotlight
  • LEADERSHIP
    • Global Leaders
    • Incredible Journeys
    • The Founder
    • PRO Speak
  • INDUSTRY
    • Education
    • Modern Healthcare
    • Travel & Tourism
  • FEATURES
    • Life
    • B&L Dialogue
    • Videos Series
  • About Us
    • Brands and Leaders INDIA
    • Advertise with us
    • Privacy Policy
    • Contact Us
Home » Modern Healthcare

Cipla & Wellthy Therapeutics Announce Partnership to offer Digital Therapeutics for Diabetes and Cardiovascular Diseases

Ankit Saxena Posted On March 10, 2019
0
35 Views
3


0
Shares
  • Share On Facebook
  • Tweet It

Cipla Limited and Wellthy Therapeutics Private Limited announced that they have entered into a partnership to offer a combination of pharmacotherapy and digital therapeutics for improved patient outcomes in the chronic therapies of diabetology and cardiology. Under the agreement, a multi-lingual clinically-validated digital disease management platform will be made available to patients living with diabetes or cardiovascular diseases via doctors’ clinics or co-packaging on select Cipla brands. The platform brings together behavioural science, real world clinical evidence and artificial intelligence to provide real time monitoring, coaching and advice to patients, and virtual clinical assistance to doctors. This partnership is a result of Cipla’s campaign, Innoventia, which was envisioned as a first-of-its-kind challenge by an Indian pharmaceutical company to encourage innovation-led entrepreneurship and to harness disruptive ideas in healthcare to fulfil unmet patient needs.

.@Vohra_Umang on how @Cipla_Global plans to uphold its legacy to make healthcare accessible to all.
Report by @ETPrime_com : https://t.co/TNNLZlNywb pic.twitter.com/dj8b3wuMF8

— Cipla (@Cipla_Global) November 19, 2018

Umang Vohra, MD & Global CEO of Cipla, said, “The future of healthcare will be driven by increased use of technology, and this partnership gives Cipla the ability to offer this combination of prescription drugs and artificial intelligence-powered digital therapeutics to patients in cardio-metabolic health. It will allow patients to make informed decisions and take charge of their own health. By pairing our pharmacotherapy strengths with the digital approach to healthcare taken by Wellthy Therapeutics, Cipla will add to its diversified portfolio in the cardio-metabolic area to provide holistic care to patients from awareness, diagnosis and compliance to wellbeing.”

Abhishek Shah, Co-founder & CEO of Wellthy Therapeutics, said, “We are excited to work with Cipla to bring digital therapeutics to patients in India. Companion digital therapeutics are redefining the treatment of chronic conditions, by helping personalise and simplify disease management for patients, and driving precision clinical insights to clinicians. With the combination of Cipla’s world class formulations and clinically validated digital therapeutics of Wellthy Therapeutics, we look forward to helping empower and inspire millions of patients to achieve better, sustainable health outcomes.” Cardiovascular Diseases (CVDs) are the leading cause of mortality in India today, cutting across the urban-rural divide. Diabetes and hypertension are significant risk factors leading to CVDs. Over 72 million1 Indians are estimated to be diabetic while approximately 10% of the population is estimated to be pre-diabetic2 , and 29% of the population is estimated to be hypertensive3 .

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology and CNS segments are well-known. Our 44 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India, 3rd largest in the pharma private market in South Africa, and is among the most dispensed generic players in the US. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders.

Post Views: 35
0
Shares
  • Share On Facebook
  • Tweet It




You may also like
Internationally Renowned Oncologist, Dr. Anil K. D’Cruz is Now Associated With Apollo Hospitals as Director, Oncology
June 18, 2019
Parvathy Hospital Takes Cartilage Repair to the Next Level
June 11, 2019
Rainbow Group of Hospitals Launches Rainbow Children’s Heart Institute at Hyderabad
June 11, 2019
Siemens introduces its latest MRI, Ultrasound and digital solutions at the IRIA 2019
Read Next

Siemens introduces its latest MRI, Ultrasound and digital solutions at the IRIA 2019

Leave A Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • FEATURES

    • Corona Warriors Of India : Sonu Sood, Minal Dakhave...
      May 27, 2020
    • B&L DIALOGUE : MR. DINESH VYAS, Sr.Vice President Marketing,...
      May 17, 2020
    • 8 Mistakes that can kill startups
      May 13, 2020
    • Helping you avoid COVID-19 online security risks
      May 7, 2020
    • B&L DIALOGUE : MR. PANKAJ PODDAR, CEO, COSMO FILMS
      May 7, 2020

  • Like Us On Facebook

    Facebook Pagelike Widget
  • Latest News

    • Tata AIA Life Insurance Hosts Virtual Health and Wellness...
      September 2, 2020
    • Datacultr selected in Finance Forward MENA 2020
      September 2, 2020
    • Tommy Hilfiger Accelerates Sustainability Journey With...
      September 1, 2020
    • Melange by Lifestyle, Announces Deepika Padukone as Brand...
      August 12, 2020
    • Reveal Acquires NexLP to become the leading AI-powered...
      August 12, 2020


  • Home
  • Brands and Leaders INDIA
  • TV Series
  • Advertise with us
  • Contact Us
© Copyright BRANDS & LEADERS 2020
Press enter/return to begin your search